ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 2694

Variations in the Metabolome in Response to Disease Activity of Rheumatoid Arthritis

Zuzana Tatar1, Carole Migne2, Mélanie Petera3, Estelle Pujos Guillot4, Philippe Gaudin5,6, T Lequerré7, Hubert Marotte8, Jacques Tebib9 and Martin Soubrier1, 1Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, 2Metabolomic Plateform INRA, Theix-Clermont-Ferrand, France, 3Metabolomic Plateform, INRA, Theix -Clermont-Ferrand, France, 4Metabolomic Plateform, INRA, Theix-Clermont-Ferrand, France, 5Rheumatology, University Hospital, Grenoble, France, 6Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, 7Rheumatology Department and INSERM U 905, CHU Hôpitaux de Rouen, Rouen, France, 8INSERM 1059 / LBTO, Université de Lyon, Saint-Etienne; Rheumatology Department, Saint-Etienne, France, 9Rheumatology Department, Centre Hospitalier Lyon-Sud, Pierre-Bénite Lyon, France

Meeting: ACR/ARHP Annual Meeting 2015

Date of first publication: September 29, 2015

Keywords: anti-TNF therapy, Biomarkers, drug treatment, metabolomics and rheumatoid arthritis (RA)

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster Session III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Anti-TNF-alpha therapies are able to control rheumatoid arthritis (RA) disease activity and to limit structural damage. Nevertheless, no predictive factor of response to anti-TNF-alpha, has yet been identified. The metabolic profile can vary in response to different inflammatory rheumatisms and hence determining this profile can considerably improve diagnosis and, consequently, prognosis.

The aim of this study was to determine, by mass spectrometry, whether there is a variation in the metabolome in patients treated with anti-TNF alpha in order to predict the therapeutic response.

Methods:

Blood samples were taken before (M0) the initiation of anti-TNF-alpha treatment in 140 patients with active RA. Plasma was deproteinised, extracted and analysed by coupled reverse phase chromotography / QToF mass spectrometry. Extracted and normalized ions were considered in univariate and ANOVA analysis and were confronted to PLS-DA (partial least-squares regression-discriminant analysis).  An OSC (Orthogonal Signal Correction) were also used in order to filter data from unwanted non-related effects. Disease activity scores, obtained at M0 and M6, and metabolome variation findings were correlated to identify a metabolite that is predictive of therapeutic response to anti-TNF-alpha.

Results: After 6 months of anti-TNF therapy, 100 patients were considered as good responders and 40 patients as non-responders according to EULAR criteria. Metabolomic investigations suggested two different metabolic fingerprinting splitting good responders group and non-responders group. A global effect of discriminative ions is concrete even if we could not report one single discriminating biomarker that could simplify the daily management of RA. The univariate analysis in positive mode revealed 24 significant ions (p < 0,05) and 31 significant ions in negative mode (p < 0,05). Once intersected with PLS results, only 35 ions remained. Especially, carbohydrate derivates seemed to be determining of therapeutic response.

Conclusion: This is the first study describing metabolic profiling in response to anti-TNF-alpha treatments using plasma samples. Our study highlighted two different metabolic fingerprinting splitting good responder group and non-responder group.


Disclosure: Z. Tatar, None; C. Migne, None; M. Petera, None; E. Pujos Guillot, None; P. Gaudin, None; T. Lequerré, None; H. Marotte, None; J. Tebib, None; M. Soubrier, None.

To cite this abstract in AMA style:

Tatar Z, Migne C, Petera M, Pujos Guillot E, Gaudin P, Lequerré T, Marotte H, Tebib J, Soubrier M. Variations in the Metabolome in Response to Disease Activity of Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/variations-in-the-metabolome-in-response-to-disease-activity-of-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARHP Annual Meeting 2015

ACR Meeting Abstracts - https://acrabstracts.org/abstract/variations-in-the-metabolome-in-response-to-disease-activity-of-rheumatoid-arthritis/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology